For those with confirmed growth hormone deficiency, the appropriate pathway remains referral to an NHS endocrinologist for formal assessment, biochemical testing, and, where indicated, initiation of licensed somatropin therapy under NICE TA188 criteria
The results are expected by the end of 2025, and if they confirm what the observational studies are suggesting, it could open up a whole new use case for GLP-1 medications in neurology
Bekhbat M, Treadway M, Felger J
When those receptors are stimulated more persistently, GI effects intensify
Similarly, the oral GLP-1 RA will also need to demonstrate their cardiovascular safety in these populations (NCT05803421)